Brain Metastases Clinical Trial
Official title:
A Phase II, Prospective Clinical Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Brain Metastases of Squamous Non-small Cell Lung Cancer
This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain metastases who had not previously received systemic therapy.
Status | Recruiting |
Enrollment | 41 |
Est. completion date | June 30, 2023 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Histologically or cytologically confirmed squamous non-small cell lung cancer; 2. Asymptomatic brain metastases or brain metastases that are relieved by dehydration therapy and remain clinically stable for at least 2 weeks 3. MRI confirmed tumor parenchymal metastases, = 3 brain lesions; or patients with 1-2 brain lesions but do not require local treatment or refuse local treatment. At least one measurable lesion in the brain lesion must be = 5mm in diameter; patients with local meningeal metastasis are allowed, but those with extensive meningeal metastasis are not included 4. Patients with stable brain metastasis symptoms after stereotactic radiotherapy are allowed (the number of stereotactic radiotherapy lesions is not more than 3) 5. No prior systemic treatment for metastatic NSCLC 6. Tumor tissue biomarker detection results must meet the following conditions at the same time: (1)EGFR mutation negative.(2)ALK rearrangement negative.(3)There are sufficient tissue samples for PD-L1 detection 7. Aged = 18 years and = 75 years 8. ECOG (Eastern Cooperative Oncology Group) performance status = 1 9. Life expectancy of more than 3 months 10. Have adequate organ function as indicated by the following laboratory values 11. Written informed consent before any trial-related procedures are performed Exclusion Criteria: Subjects with any of the following criteria may not be included in this study: 1. With mixed adenosquamous carcinoma or small cell lung cancer mainly composed of adenocarcinoma 2. Currently participating in interventional clinical study treatment, or have received other investigational drugs or investigational device treatment before the first dose; 3. Received prior therapies targeting PD-1, PD-L1, CTLA-4, cytotoxic chemotherapy or other immune checkpoints inhibitors 4. Received solid organ or blood system transplantation 5. Have active autoimmune diseases requiring systemic therapy within 2 years before the first dose 6. Diagnosis of immunodeficiency or systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of the study 7. History of non-infectious pneumonia requiring glucocorticoid therapy or current interstitial lung disease within 1 year before the first dose 8. Known history of human immunodeficiency virus (HIV) infection 9. Untreated active hepatitis B; Note: hepatitis B subjects who meet the following criteria are also eligible: a) HBV viral load must be < 1000 copies/ml before the first dose, and subjects should receive anti-HBV therapy to avoid viral reactivation throughout the study chemotherapy drug treatment b) For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation needs to be closely monitored; 10. Subjects with active HCV infection 11. Pregnant and lactating women 12. Malignant tumors other than NSCLC within 5 years before screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell epithelial skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | intracranial progression-free survival (iPFS) after treatment with tislelizumab plus chemotherapy in patients with asymptomatic brain metastases or stable symptoms after stereotactic radiotherapy (according to RECIST 1.1) | Intracranial Progression-free survival is defined as the time from the starting date of study drug to the date of first documentation of intracranial disease progression or death, whichever occurs first | 12months | |
Secondary | intracranial objective response rate (iORR) (according to RECIST 1.1) | iORR is defined as the proportion (%) of patients with complete or partial response of intracranial lesions | 12months | |
Secondary | objective response rate (ORR) (according to RECIST 1.1) | ORR is defined as the proportion (%) of patients with complete or partial response of overall lesions | 12months | |
Secondary | progression-free survival (PFS) (according to RECIST 1.1) | Progression-free survival is defined as the time from the starting date of study drug to the date of first documentation of overall disease progression or death, whichever occurs first. | 12months | |
Secondary | overall survival (OS) (according to RECIST 1.1) | OS is defined as the time from the starting date of study drug to the date of death due to any cause | 24months | |
Secondary | Safety of treatment was assessed using NCI-CTCAEv5 version | TEAEs graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 | 24months | |
Secondary | Assessment of neurocognitive deterioration | Neurocognitive impairment according to Hopkins Verbal Learning Test-Revised(HVLT-R) | 24months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04474925 -
Pre- Versus Post-operative SRS for Resectable Brain Metastases
|
Phase 3 | |
Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Completed |
NCT03189381 -
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
|
N/A | |
Completed |
NCT02082587 -
Toronto BNB Pilot Study
|
N/A | |
Terminated |
NCT01551680 -
A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases
|
Phase 1 | |
Terminated |
NCT00717275 -
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05048212 -
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
|
Phase 2 | |
Recruiting |
NCT03714243 -
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
|
N/A | |
Recruiting |
NCT05573815 -
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
Completed |
NCT04170777 -
Perfexion Registration Using CBCT
|
||
Recruiting |
NCT03027544 -
Tomotherapy for Refractory Brain Metastases
|
N/A | |
Completed |
NCT04178330 -
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
|
N/A | |
Terminated |
NCT02187822 -
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
|
Phase 1 | |
Terminated |
NCT00538343 -
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
|
Phase 2 |